Please login to the form below
CALD gene therapy
This page shows the latest CALD gene therapy news and features for those working in and with pharma, biotech and healthcare.
EU approves bluebird bio’s CALD gene therapy Skysona
The European Commission (EC) has approved bluebird bio’s gene therapy Skysona for the rare inherited neurological disease cerebral adrenoleukodystrophy (CALD). ... The EC has cleared Skysona (elivaldogene autotemcel) for the treatment of early CALD in
Latest news
-
bluebird bio’s CALD gene therapy Skysona gains positive opinion from CHMP
bluebird bio’s cerebral adrenoleukodystrophy (CALD) gene therapy Skysona has moved closer towards EU approval after gaining a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for ... bluebird bio's Skysona is a
-
bluebird bio reveals long-term data for Lenti-D gene therapy in CALD
bluebird bio has revealed new data from its clinical development programme for Lenti-D gene therapy in cerebral adrenoleukodystrophy (CALD). ... bluebird bio’s Lenti-D (eli-cel/elivaldogene autotemcel) is a potential one-off gene therapy designed to
-
EMA accepts application for bluebird bio’s Lenti-D in CALD
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for bluebird bio’s Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD). ... Bluebird bio's Lenti-D (eli-cel/elivaldogene autotemcel) is a potential
-
bluebird bio reveals further encouraging data for CALD gene therapy
Study shows continued benefit in treatment of rare disease. Last year, Bluebird Bio claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – it has now ... Lenti-D is Bluebird’s lead gene
-
bluebird bags breakthrough status for CALD gene therapy
News comes after impressive data from a phase II/III trial. Bluebird Bio has claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – a rare ... Bluebird’s gene therapy approach could do away
bluebird bio’s CALD gene therapy Skysona gains positive opinion from CHMP
bluebird bags breakthrough status for CALD gene therapy
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Europe is the test ground for the gene therapy pioneer’s outcomes-based model, which could set the standard for the emerging sector. ... pipeline. This incudes Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), a rare,
Bluebird: on a mission to ‘recode’ the DNA of healthcare
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Distracted boyfriend: the secret of a successful long-distance relationship
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Vertex gains FDA fast track designation for diabetes stem cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Roche appoints Philip Atkinson to new global role
- AZ’s comeback drug cediranib stumbles in phase 3 trial
- MHRA outlines two-year delivery plan with ‘patient first’ focus
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
